Drug therapy in rheumatology nursing / edited by Sarah Ryan. — 2nd ed.

1. Rheumatism—Chemotherapy. 2. Rheumatism—Nursing.
I. Ryan, Sarah. II. Hill, Jacqueline, 1946—. Rheumatology.

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.
Contents

List of Contributors xiii
List of Figures xv
List of Tables xvii
Preface xix

1 Rheumatological Conditions 1
   Janet Cushnaghan and Jackie McDowell

   1.1 Introduction 1
   1.2 Features of rheumatic conditions 2
       Pain 3
       Stiffness 3
       Swelling 3
       Joint involvement 3
       Function 3
   1.3 Epidemiology 4
   1.4 Anatomy and physiology of the musculoskeletal system 5
       Muscle 5
       Bone 5
       Cartilage 6
       Synovium 6
       Ligaments and tendons 6
       Tendon sheaths and bursae 6
       Synovial joints 7
       Physiology 7
       Circulation 7
       Lymphatics 7
       Intra-articular pressure 8
       Motion 8
       Innervation 8
       Temperature 8
   1.5 Anatomy and physiology of the musculoskeletal system in inflammatory arthritis 9
       Immunopathogenetic mechanisms 9
       Susceptibility 10
       Synovitis 11
1.6 An overview of the rheumatological conditions most commonly encountered in Western Europe 12
  Rheumatoid arthritis 12
  Juvenile idiopathic arthritis 19
  Polymyalgia rheumatica 21
  Inflammatory arthritis associated with spondylitis 22
  Ankylosing spondylitis 22
  Reiter’s syndrome 23
  Psoriatic arthritis 24
  Septic arthritis 26
  Reactive arthritis 28
  Triggering factors 29
  Osteoarthritis 30
  Fibromyalgia syndrome 32
  Connective tissue disease 34
  Systemic lupus erythematosus 34
  Scleroderma (systemic sclerosis) 36
  Inflammatory muscle disease (polymyositis) 41

1.7 The impact of rheumatological conditions on physical, psychological, social and occupational function 45
  Personal impact of arthritis 47
  Financial impact of arthritis 48
  Impact on education 48
  Impact on employment 49
  The role of social support 50
  Impact on family relationships 50
  Depression 52

References 53

2 Drug Therapy 61
Sarah Ryan, Susan Oliver and Ann Brownfield

2.1 Pain 61
  Physiology of pain 62
  Pain receptors 63
  The role of the brain 64
  Physiological effects of acute pain 64

2.2 Pharmacological interventions in rheumatology 65
  Non-opioid analgesia 65
  Compound analgesia 66
  Opioids 66
  Antidepressant drugs 71
  Non-steroidal anti-inflammatory drugs 71
2.3 Disease Modifying Anti-rheumatic Drugs (DMARDs) 81
   Use of DMARDs 81
   Early treatment of RA 81
   Combination therapy 82
   Mode of action and pharmacokinetics of DMARDs 82
   The anti-malarials 83
   Sulfasalazine 85
   D-penicillamine 85
   Myocrisin 86
   Auranofin 87
   Methotrexate 87
   Leflunomide 88
   Azathioprine 88
   Cyclophosphamide 89
   Ciclosporin 89
   Chlorambucil 90
   Phenylbutazone 90
   Dapsone 91
   Minocycline 91
   Mycophenolate Mofetil 91

2.4 Biologic therapies 92
   Introduction 92
   Biologically engineered therapies (biologics) 93
   Classifications — biologic therapies 93
   Mode of action — general 94
   Adverse reactions to biologic therapies 95
   Biologic therapies — treatment options 104
   General issues related to the mode of action — for all anti-TNFα therapies 107
   Side effects that should be considered for all anti-TNFα 108
   Pregnancy and breastfeeding 111
   Immunization 112
   Specific information on anti-TNFα 112
   Biologic therapies — patient issues 119

2.5 The use of steroids in the treatment of rheumatic disease 119
   Glucocorticoids 120
   The use of steroids in rheumatoid arthritis 120
   Corticosteroid sparing agents 121
   Adverse effects of corticosteroids 121
   The use of corticosteroids in other rheumatological conditions 123
   Bone mineral metabolism 124
   Peptic ulceration 125
   Atherosclerosis 125
   Reducing the dose of corticosteroids 125
Pulsed corticosteroids 125
Intramuscular corticosteroids 126
Intra-articular/soft tissue injections of corticosteroids 126

2.6 Disorders of purine metabolism: gout 126
   Hyperuricaemia 126

2.7 Nurse prescribing 131
   Who should prescribe? 132
   Independent prescribing 132
   Supplementary prescribing 133
   Educational preparation 134
   Professional responsibilities 134
   Evaluation of prescribing 134

2.8 Self-medication 136
   The case for self-medication 136
   Advantages of self-medication 137
   Stages in the implementation of self-medication 138

2.9 Complementary medicine 139
   Diet 140
   Massage 141
   Aromatherapy 142
   Reflexology 142
   Acupuncture 142
   Herbal medicine 142
   Naturopathy 143
   Holism 143

2.10 Glucosamine 143
2.11 Capsaicin 145
Conclusion 145

Appendix 2.A What happens next? 145
Appendix 2.B Guidelines for nurses on the use and administration of
intra-articular injections 146
References 148
Appendix 2.C Patient group direction for the administration of
methylprednisolone injection 40 mg/ml by intramuscular
injection 148
Case scenarios 152
References 152

3 The Role of the Nurse in Drug Therapy 163
   Sarah Ryan and Margaret Ann Voyce

3.1 What is rheumatology nursing? 163
   The nurse—patient relationship 165
3.2 Telephone advice lines 166
3.3 The philosophy of rheumatology nursing 166
3.4 The role of the nurse in drug therapy 168
   Empowerment 168
3.5 The commencement of DMARDs 169
   Patient preparation 169
   Monitoring clinics 170
   Documentation 172
   The use of protocols 172
   Drug monitor clinic protocols 174
3.6 Investigations 177
   Haematological investigations 177
   Biochemical investigations 181
   Assessment of rheumatic disease activity 182
3.7 Urine testing 184
   Appearance 185
   Odour 185
   Measurement of specific gravity 185
   Record keeping 186
3.8 Drugs that require surveillance 187
   Gold (myocrisin) therapy 187
   Auranofin (ridula) therapy in RA 190
   D-penicillamine (distamine) 191
   Sulfasalazine en therapy (salazopyrin) 194
   Methotrexate 196
   Azathioprine (imuran) therapy 199
   Cyclophosphamide (endoxana) therapy 201
   Ciclosporin 203
   Chlorambucil 205
   Phenylbutazone (butacote) 206
   Dapsone 207
   Minocycline (minocin) 208
   Leflunomide 208
   Mycophenolate Mofetil 211
3.9 Vaccination 212
3.10 Pregnancy 212
   Contraception 214
3.11 The role of the community team in drug therapy 214
   Minimizing confusion 215
3.12 Community drug monitoring 216
   Documentation 217
   GPs’ concerns relating to practice-based monitoring 218
   Patients’ experiences of drug monitoring 218
3.13 Community clinics 218
3.14 General practice 219
3.15 Evaluation of community clinics 219
    Potential problems with consultant-based community clinics 220
3.16 Nurse-led community clinics 220
3.17 New ways of utilizing outpatient appointments 222
3.18 Drug therapy and osteoporosis 222
    Classification of osteoporosis 222
    Risk factors for osteoporosis fracture 223
    Investigations for osteoporosis 224
3.19 Hormone replacement therapy (HRT) 224
3.20 Pain management 225
3.21 Drugs to reduce fracture risk 225
    Bisphosphonates 225
    Etidronate 225
    Alendronate Sodium (fosamax) 225
3.22 Other drug treatments 226
    Calcitonin 226
    Calcium 226
    Vitamin D 227
    Calcitriol 227
    Formation stimulating agents 227
    Strontium ranelate (protelos) 227
3.23 Prevention (lifestyle strategies) 228
    Diet 228
    Smoking 228
    Alcohol 228
    Exercise 228
    Falls 228

Conclusion 229
Appendix 3.A 229
Appendix 3.B 232
References 235

4 Patient Education and Adherence with Drug Therapy 243

Jackie Hill

4.1 Definitions of patient education 243
4.2 Useful theories and models 244
    Learned helplessness theory 245
    Stress and coping theory 245
    Health belief model 246
    Self-efficacy theory 247
Changing self-efficacy 248
Mastery of skills 248
Modelling 249
Persuasion 250
Reinterpretation of physiological state 250

4.3 Purpose of patient education 250
4.4 Limitations of patient education 251
4.5 Role of the nurse in patient education 252

4.6 Planning a patient education programme 254

4.7 Individual patient education 257

4.8 Teaching in groups 261
4.9 Opportunity education 262

4.10 The arthritis self-management programme 262
4.11 What to teach 263

4.12 Teaching aids 267

4.13 The optimum timing of patient education 271

Patient education and some fundamental aspects of nursing 252
Patient education and therapeutic nursing 252
Reciprocity 252
Professional closeness 253

The learning environment 254
Demographic considerations 255
Disease duration 255
Age range 255
Diagnosis 256
Mixed educational ability 256
The type of programme 256

Preferences of drug therapy 257
Assess the patients’ knowledge of drugs 258
Establishing shared goals 259
Preferred method of information transfer 259
Contracting 260
The activity to be accomplished 260
The plan of action 260
Checking that the contract is realistic 260

Assess the patients’ knowledge of drugs 258

What to include 265
Risks and adverse effects 266

Videos and CDs 270
Audiocassettes 270
Computer programs 270

Readiness for change 271
CONTENTS

4.14 Patient education and adherence 272
Conclusion 273
Appendix 4.A Methotrexate information sheet 274
References 277

Index 283
List of Contributors

Ann Brownfield, RGN, MSc, BSc (Hons)
Clinical Nurse Specialist, North and South Primary Care Trust, Haywood Hospital, Stoke on Trent

Janet Cushnagan, MSc, MCSP
MRC ERC, Southampton General Hospital, Southampton

Jackie Hill, PhD, MPhil, RN, FRCN
Arc senior lecturer in rheumatology nursing and Co-director ACUMeN, Chapel Allerton Hospital, Leeds

Jackie A McDowell, BSc (Hons), RGN, NDN
Clinical nurse specialist, Hereford Hospitals NHS Trust, Hereford

Susan Oliver, MSc
Nurse Consultant Rheumatology, Litchdon Medical Centre, Devon

Sarah Ryan, RGN, PhD, MSc, FRCN
Nurse Consultant Rheumatology, North and South Primary Care Trust, Haywood Hospital, Stoke on Trent

Margaret Ann Voyce, SRN
Rheumatology Nurse Practitioner, Rheumatology Department, Royal Cornwall Hospital, Truro